Call notice for a shareholders’ meeting of ALTERNATIVE GENE EXPRESSION, S.L.

Jun 14 2021

The managing body of ALTERNATIVE GENE EXPRESSION, S.L. (the “Company”), in accordance with the statutory and bylaw provisions in force, has resolved to call the shareholders of the Company to a shareholders’ meeting, to be held by conference call on 29 June 2021, at 11:00 am, to deliberate and decide on the items on the following agenda:

  1. Ratification of the valid constitution of the general shareholders’ meeting, the agenda and the offices of chairman and secretary
  2. Examination and approval, as the case may be, of the financial statements and of the conduct of management of the Company by the managing body or the year ended 31 December 2020
  3. Allocation of income or loss for the year ended 31 December 2020
  4. Delegation of powers
  5. Reading and approval, as the case may be, of the minutes


Dial-in details for the general shareholders’ meeting are the following:

Pursuant to the provisions of article 272 of the Consolidated Text of the Spanish Companies Act, all shareholders are informed of their right to obtain from the Company, immediately and free of charge, the individual financial statements that will be submitted for approval by the general shareholders’ meeting.


In Madrid, on 14 June 2021.

Mr. José Ángel Martínez Escribano
Chairman of the board of directors

Download call notice in PDF

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex´ first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit